secwatch.observer — SEC 8-K summary
======================================

Issuer:     Akebia Therapeutics, Inc. (AKBA)
CIK:        0001517022
Form:       8-K
Filed at:   2024-03-28T23:59:59+00:00
Accession:  0001517022-24-000031
Event type: regulatory
Sentiment:  positive
Materiality: 0.85
Item codes: 7.01, 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Akebia Therapeutics receives FDA approval for Vafseo (vadadustat) for dialysis patients
--------------------------------------------------------------------------------

- FDA approved Vafseo for anemia due to CKD in adults on dialysis ≥3 months; boxed warning for thrombosis risks.
- Vafseo is a once-daily oral HIF-PH inhibitor; already approved in 37 countries.
- ~500,000 U.S. adult dialysis patients suffer from CKD anemia.
- Approval based on INNO2VATE Phase 3 program data published in NEJM 2021; plus Japan post-marketing data.
- Akebia plans U.S. launch with commercial team and CSL Vifor partnership; conference call March 28.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1517022/000151702224000031/0001517022-24-000031-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1517022/000151702224000031/akba-20240327.htm
  HTML page:      https://secwatch.observer/filing/0001517022-24-000031

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer